CHONGKUNDANG HOLDINGS CORP.
Financials
Valuation Metrics
CHONGKUNDANG HOLDINGS CORP.'s Market Cap is ₩1899B. At end of 2025 it was ₩2317B. Ranked #878 of 2,421 in KR market (top 36%), #464 of 781 on KOSPI (top 59%), #93 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 40%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 189.87B KRW | KR#878/2,421 Sec#93/231 |
| Revenue | 961.64B KRW | KR#423/2,421 Sec#16/231 |
| Net Income | 70.66B KRW | KR#326/2,421 Sec#24/231 |
| Total Assets | 1.75T KRW | KR#327/2,421 Sec#14/231 |
| Net Assets | 933.87B KRW | KR#303/2,421 Sec#18/231 |
| Employees | 37 | KR#2,154/2,421 Sec#199/231 |
| Value | ||
| P/E | 2.69x | KR#122/2,421 Sec#5/231 |
| P/B | 0.20x | KR#124/2,421 Sec#5/231 |
| PEG | 0.03x | KR#224/2,421 Sec#13/231 |
| P/S | 0.20x | KR#360/2,421 Sec#7/231 |
| EV/EBITDA | 13.33x | KR#779/2,421 Sec#44/231 |
| FCF Yield | 10.64% | KR#585/2,421 Sec#22/231 |
| Profitability | ||
| ROE | 7.57% | KR#838/2,421 Sec#59/231 |
| ROA | 4.04% | KR#865/2,421 Sec#70/231 |
| Op. Margin | 5.80% | KR#863/2,421 Sec#65/231 |
| Revenue Growth | 1.43% | KR#1,433/2,421 Sec#141/231 |
| Earnings Growth | 99.74% | KR#390/2,421 Sec#26/231 |
| Financial Health | ||
| Debt Ratio | 87.24% | KR#1,435/2,421 Sec#167/231 |
| Total Debt | 598.12B KRW | KR#273/2,421 Sec#8/231 |
| FCF | 20.20B KRW | KR#522/2,421 Sec#29/231 |
| Cash | 44.54B KRW | KR#792/2,421 Sec#48/231 |
| Current Ratio | 0.84x | KR#1,897/2,421 Sec#185/231 |
| Net Debt/EBITDA | 9.92x | KR#1,223/2,421 Sec#89/231 |
| Dividend | ||
| Div. Yield | 3.70% | KR#478/2,421 Sec#20/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -23.12% | KR#1,353/2,421 Sec#96/231 |
| 1M Return | -2.32% | KR#1,502/2,421 Sec#117/231 |
| From 52W High | -31.83% | KR#596/2,421 Sec#35/231 |
| 1Y MDD | -31.66% | KR#297/2,421 Sec#20/231 |
| Trading | ||
| Volume | 1,680 shares | KR#2,288/2,421 Sec#216/231 |
| Trading Value | 63.6M KRW | KR#1,754/2,421 Sec#177/231 |
| Foreign Own. | 3.21% | KR#1,227/2,421 Sec#113/231 |
| Per Share | ||
| EPS | 14,105 KRW | KR#76/2,421 Sec#5/231 |
| BPS | 186,406 KRW | KR#76/2,421 Sec#2/231 |
Company Info
Jonggeundang Holdings, established in 1941, became a registered pharmaceutical company in 1956 before transitioning to a holding company structure in 2013 through a spin-off of its investment and pharmaceutical divisions. As a holding company, its main revenue sources are management consulting fees, brand usage fees, and dividend income, with a focus on governance and management through subsidiary equity ownership. It manages key subsidiaries such as Jonggeundang Health, Gyeongbo Pharmaceutical, Jonggeundang Bio, and Jonggeundang Industrial, along with its subsidiary Jonggeundang, fostering synergy and value through independent management and performance evaluation. The company is headquartered in Seodaemun-gu, Seoul Metropolitan City.